Erratum: Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models (Journal of Clinical Investigation (2012) 122, 4 (1541-1552) DOI: 10.1172/JCI58765);Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Journal of Clinical Investigation

Volumn 122, Issue 4, 2012, Pages 1541-1552

  Ma, Cynthia X ^a   Cai, Shirong ^a   Li, Shunqiang ^a   Ryan, Christine E ^a   Guo, Zhanfang ^a   Schaiff, W Timothy ^a   Lin, Li ^a   Hoog, Jeremy ^a   Goiffon, Reece J ^a,b   Prat, Aleix ^c   Aft, Rebecca L ^a,d   Ellis, Matthew J ^a   Piwnica Worms, Helen ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; AZD 7762; CHECKPOINT KINASE 1; IRINOTECAN; PROTEIN KINASE C INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR MODEL; XENOGRAFT;

EID: 84859726248     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64256     Document Type: Erratum

References (54)

1. Carey LA, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295(21):2492-2502. (Pubitemid 43854964)
2. Kim SH, Li C, Maller JL. A maternal form of the phosphatase Cdc25A regulates early embryonic cell cycles in Xenopus laevis. Dev Biol. 1999; 212(2):381-391. (Pubitemid 29387943)
3. Shimuta K, Nakajo N, Uto K, Hayano Y, Okazaki K, Sagata N. Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition. EMBo J. 2002;21(14):3694-3703. (Pubitemid 34787043)
4. Sorensen CS, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 2003;3(3):247-258. (Pubitemid 37443880)
5. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A. 2002;99(23):14795-14800. (Pubitemid 35334563)
6. Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol. 2003;23(21):7488-7497. (Pubitemid 37271450)
7. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001;410(6830):842-847. (Pubitemid 32303786)
8. Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace AJ Jr, Bulavin DV. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle. 2003;2(5):473-478.
9. Hassepass I, Voit R, Hoffmann I. Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem. 2003;278(32):29824-29829. (Pubitemid 36962370)
10. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. oncogene. 2005;24(23):3786-3796.
11. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res. 1996;2(5):791-797. (Pubitemid 26168931)
12. Fuse E, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998; 58(15):3248-3253. (Pubitemid 28371060)
13. Yu L, et al. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem. 1998; 273(50):33455-33464.
14. Graves PR, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem. 2000; 275(8):5600-5605. (Pubitemid 30115197)
15. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 2000; 60(8):2108-2112. (Pubitemid 30225168)
16. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003;63(1):31-35. (Pubitemid 36070415)
17. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88(14):956-965. (Pubitemid 26239383)
18. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2010;17(2):88-96.
19. Tse AN, Carvajal R, Schwartz GK. Targeting Checkpoint Kinase 1 in Cancer Therapeutics. Clin Cancer Res. 2007;13(7):1955-1960. (Pubitemid 46649860)
20. Zabludoff SD, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7(9):2955-2966.
21. Kuperwasser C, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A. 2004;101(14):4966-4971. (Pubitemid 38469186)
22. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin oncol. 2009; 27(8):1160-1167.
23. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
24. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol oncol. 2011;5(1):5-23.
25. Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biol Ther. 2003;2(3):233-235.
26. Xu B, Kim S-T, Kastan MB. Involvement of Brca1 in S-phase and G2-phase Checkpoints after Ionizing Radiation. Mol Cell Biol. 2001;21(10):3445-3450. (Pubitemid 32381780)
27. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30(1):83-89. (Pubitemid 43740213)
28. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN- 01 (7-hydroxystaurosporine). oncogene. 2002; 21(11):1727-1738.
29. Stewart SA, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003; 9(4):493-501. (Pubitemid 36356735)
30. Arienti KL, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005;48(6):1873- 1885. (Pubitemid 40396318)
31. Ding L, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999-1005.
32. Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917. (Pubitemid 40559005)
33. Fracasso PM, et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011;67(6):1225-1237.
34. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A. 2002; 99(23):14795-14800. (Pubitemid 35334563)
35. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther. 2006;5(8):1935-1943. (Pubitemid 44336564)
36. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle. 2005;4(1):131-139. (Pubitemid 41038942)
37. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther. 2007; 6(3):935-944. (Pubitemid 46554563)
38. Karnitz LM, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol. 2005;68(6):1636-1644. (Pubitemid 41654347)
39. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle. 2004;3(9):1177-1181. (Pubitemid 40268636)
40. Gasco M Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002;4(2):70-76. (Pubitemid 34248123)
41. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13(2):293-325. (Pubitemid 43886660)
42. Malamou-Mitsi V, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann oncol. 2006;17(10):1504-1511. (Pubitemid 44542035)
43. Andersson J, et al. Worse survival for TP53 (p53)- mutated breast cancer patients receiving adjuvant CMF. Ann oncol. 2005;16(5):743-748. (Pubitemid 40767094)
44. Bull SB, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin oncol. 2004;22(1):86-96. (Pubitemid 41095118)
45. Smith PD, et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. oncogene. 1999;18(15):2451-2459.
46. Phillips KA, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst. 1999; 91(5):469-473.
47. De Cremoux P, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91(7):641-643. (Pubitemid 29194052)
48. Angele S, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000;6(9):3536-3544.
49. Sullivan A, et al. Concomitant inactivation of p53 and Chk2 in breast cancer. oncogene. 2002; 21(9):1316-1324.
50. Ho GH, et al. Genetic alterations of the p14ARFhdm2- p53 regulatory pathway in breast carcinoma. Breast Cancer Res Treat. 2001;65(3):225-232. (Pubitemid 32328543)
51. Ye XS, Fincher RR, Tang A, Osmani SA. The G2/M DNA damage checkpoint inhibits mitosis through Tyr15 phosphorylation of p34cdc2 in Aspergillus nidulins. EMBo J. 1997;16(1):182-192. (Pubitemid 27032861)
52. Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin oncol. 2011;29(17):2342-2349.
53. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image J. Biophotonics Int. 2004;11(7):36-42.
54. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873-890. (Pubitemid 28185166)